Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Issue 21 (20th July 2022)
- Record Type:
- Journal Article
- Title:
- Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Issue 21 (20th July 2022)
- Main Title:
- Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
- Authors:
- Mikhaeel, N. George
Heymans, Martijn W.
Eertink, Jakoba J.
de Vet, Henrica C.W.
Boellaard, Ronald
Dührsen, Ulrich
Ceriani, Luca
Schmitz, Christine
Wiegers, Sanne E.
Hüttmann, Andreas
Lugtenburg, Pieternella J.
Zucca, Emanuele
Zwezerijnen, Gerben J.C.
Hoekstra, Otto S.
Zijlstra, Josée M.
Barrington, Sally F. - Abstract:
- Abstract : PURPOSE: Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship between MTV and survival and to compare MTV with the International Prognostic Index (IPI) and its individual components to derive the best prognostic model. METHODS: PET scans and clinical data were included from five published studies in newly diagnosed diffuse large B-cell lymphoma. Transformations of MTV were compared with the primary end points of 3-year progression-free survival (PFS) and overall survival (OS) to derive the best relationship for further analyses. MTV was compared with IPI categories and individual components to derive the best model. Patients were grouped into three groups for survival analysis using Kaplan-Meier analysis; 10% at highest risk, 30% intermediate risk, and 60% lowest risk, corresponding with expected clinical outcome. Validation of the best model was performed using four studies as a test set and the fifth study for validation and repeated five times. RESULTS: The best relationship for MTV and survival was a linear spline model with one knot located at the median MTV value of 307.9 cm 3 . MTV was a better predictor than IPI for PFS and OS. The best model combined MTV with age as continuous variables and individual stage as I-IV. The MTV-age-stage model performed better than IPI and was also better at defining a high-risk group (3-year PFS 46.3% v 58.0% andAbstract : PURPOSE: Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship between MTV and survival and to compare MTV with the International Prognostic Index (IPI) and its individual components to derive the best prognostic model. METHODS: PET scans and clinical data were included from five published studies in newly diagnosed diffuse large B-cell lymphoma. Transformations of MTV were compared with the primary end points of 3-year progression-free survival (PFS) and overall survival (OS) to derive the best relationship for further analyses. MTV was compared with IPI categories and individual components to derive the best model. Patients were grouped into three groups for survival analysis using Kaplan-Meier analysis; 10% at highest risk, 30% intermediate risk, and 60% lowest risk, corresponding with expected clinical outcome. Validation of the best model was performed using four studies as a test set and the fifth study for validation and repeated five times. RESULTS: The best relationship for MTV and survival was a linear spline model with one knot located at the median MTV value of 307.9 cm 3 . MTV was a better predictor than IPI for PFS and OS. The best model combined MTV with age as continuous variables and individual stage as I-IV. The MTV-age-stage model performed better than IPI and was also better at defining a high-risk group (3-year PFS 46.3% v 58.0% and 3-year OS 51.5% v 66.4% for the new model and IPI, respectively). A regression formula was derived to estimate individual patient survival probabilities. CONCLUSION: A new prognostic index is proposed using MTV, age, and stage, which outperforms IPI and enables individualized estimates of patient outcome. Abstract : … (more)
- Is Part Of:
- Journal of clinical oncology. Volume 40:Issue 21(2022)
- Journal:
- Journal of clinical oncology
- Issue:
- Volume 40:Issue 21(2022)
- Issue Display:
- Volume 40, Issue 21 (2022)
- Year:
- 2022
- Volume:
- 40
- Issue:
- 21
- Issue Sort Value:
- 2022-0040-0021-0000
- Page Start:
- 2352
- Page End:
- 2360
- Publication Date:
- 2022-07-20
- Subjects:
- Oncology -- Periodicals
Cancer -- Periodicals
Oncology
Medical Oncology
Cancérologie -- Périodiques
Cancer -- Périodiques
Cancérologie
Cancer
Oncology
Oncologia
Càncer
Periodicals
616.994 - Journal URLs:
- http://www.jco.org/ ↗
http://jco.ascopubs.org/ ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1200/JCO.21.02063 ↗
- Languages:
- English
- ISSNs:
- 0732-183X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23590.xml